MedTrace Logo

Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System

NCT04249375 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2026-05-01

No results posted yet for this study

Summary

This project addresses the problem of adverse drug reactions in the three most frequently prescribed therapeutic classes of drugs in children: antibiotics, analgesics, and mental health medications.

We will conduct pilot testing of a pharmacogenomic testing panel and study how the tests and generated test results are utilized and understood by physicians, pharmacists, patients and their families.

Conditions

  • Adverse Drug Reaction (ADR)

Sponsors & Collaborators

  • Genome British Columbia

    collaborator INDUSTRY

  • Genome Canada

    collaborator OTHER

  • Dynacare Laboratories, Inc.

    collaborator UNKNOWN

  • University of British Columbia

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-20
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04249375 on ClinicalTrials.gov